Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 4.65B | 5.00B | 4.89B | 4.58B | 4.29B | 4.17B |
Gross Profit | 1.73B | 1.76B | 1.73B | 1.62B | 1.48B | 1.41B |
EBITDA | 852.98M | 819.03M | 855.15M | 889.85M | 1.04B | 792.16M |
Net Income | 554.82M | 493.20M | 540.71M | 549.50M | 688.37M | 497.84M |
Balance Sheet | ||||||
Total Assets | 6.33B | 6.39B | 6.43B | 6.39B | 6.51B | 6.34B |
Cash, Cash Equivalents and Short-Term Investments | 342.47M | 514.33M | 742.53M | 817.98M | 965.59M | 983.94M |
Total Debt | 838.64M | 789.74M | 807.31M | 826.83M | 881.17M | 1.03B |
Total Liabilities | 2.79B | 2.89B | 2.86B | 2.83B | 2.88B | 2.68B |
Stockholders Equity | 3.50B | 3.46B | 3.52B | 3.52B | 3.59B | 3.62B |
Cash Flow | ||||||
Free Cash Flow | 638.63M | 618.93M | 698.27M | 529.50M | 715.37M | 452.63M |
Operating Cash Flow | 737.18M | 724.43M | 822.63M | 756.72M | 925.81M | 658.14M |
Investing Cash Flow | -28.19M | -127.41M | -224.50M | -262.50M | -329.00M | -461.73M |
Financing Cash Flow | -759.66M | -771.02M | -651.43M | -629.90M | -870.93M | 315.14M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $9.07B | 16.67 | 15.75% | 2.48% | -6.76% | 13.90% | |
73 Outperform | $6.55B | 27.38 | 19.00% | ― | 23.86% | 79.35% | |
72 Outperform | $10.46B | 25.83 | 9.21% | ― | 3.98% | -31.18% | |
67 Neutral | $8.66B | 5,259.57 | -0.32% | ― | 1.16% | -104.62% | |
62 Neutral | $7.13B | ― | -6.42% | ― | 33.17% | 82.85% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
Amdocs Limited reported its financial results for the quarter ended June 30, 2025, showing a decline in revenue compared to the previous year. The company’s total assets slightly decreased from September 2024, while liabilities also saw a reduction. These financial results may impact Amdocs’ market positioning and stakeholder confidence, reflecting challenges in maintaining growth amidst changing market conditions.
On August 6, 2025, Amdocs Limited announced its financial results for the third quarter of fiscal 2025, reporting a revenue of $1.14 billion, which exceeded the midpoint of their guidance range. Despite an 8.4% year-over-year decline in reported revenue, the company achieved a 3.5% increase on a pro forma constant currency basis. Amdocs highlighted significant achievements, including record revenues in Europe and managed services, as well as strategic digital transformation projects with BT in the UK and Elisa in Finland. The company also secured several GenAI-related deals, enhancing its market positioning in emerging technologies. Amdocs reiterated its fiscal 2025 target for double-digit total shareholder returns, supported by enhanced profitability and robust earnings to cash conversion.